Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Valeo Pharma In-Play, New HesperCo™ Immune System Support Scientifically Demonstrated

Shares of Valeo Pharma Inc. (CSE: VPH) (Frankfurt: VP2) poised for substantial upside revaluation to reflect the major ‘company –maker’ potential in HesperCo™ as the market figures out it is set to be the subject of Covid-19 clinical trial. Valeo will benefit...
Fredrick William | September 2, 2020 |

How BioVaxys' DPX platform creates anti-cancer immune response

Discover BioVaxys’ innovative DPX™ platform, a cutting-edge lipid-based delivery system transforming immunotherapy. This video explores how the company’s proprietary technology encapsulates diverse bioactive molecules, enhancing and sustai...
Research | October 8, 2024 |

Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie

Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101. Clinical-stage immunotherapy company Alpine Immune S...
Streetwise Reports | June 19, 2020 |

Will the Second Wave Trigger Rally in Gold?

The initial health crisis seems to be under control in many countries. But this is not the end of pandemic and many epidemiologist warn against the second wave of injections. We invite you to read our today’s article about the second wave of the new coronavirus...
Arkadiusz Sieron | June 19, 2020 |

Revolutionizing immunotherapies with groundbreaking DPX platform

The following is a transcription of the above video, and The Market Online has edited it for clarity . BioVaxys Technology Corp (CSE:BIOV) is a Canadian-based clinical stage biopharmaceutical company focused on improving patient lives with novel immunotherapies. CE...
Lyndsay Malchuk | July 30, 2024 |

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously

We are initiating coverage on INmune Bio Inc. (INMB:NASDAQ) . According to the company, INmune is "Reprogramming the Innate Immune System for the Treatment of Diseases." On the surface, this sounds like a fairly standard biotech tagline, but there's a more here than me...
Streetwise Reports | December 5, 2019 |

Get Ready for a Weaker U.S. Dollar… And Stronger Gold

Unemployment in the U.S. is at a half-century low and the S&P 500 is trading at near-record highs. Nevertheless, the Federal Reserve today trimmed interest rates for the first time since the financial crisis on stalled manufacturing growth and an anticipated world econo...
Frank Holmes | August 1, 2019 |

Silver Looking Weaker than Gold

Technical analyst Clive Maund charts silver and finds that it looks "considerably weaker than gold." Silver looks considerably weaker than gold, although that is normal at this stage in the cycle. It is still considered likely that it is forming a Double Bot...
Streetwise Reports | May 22, 2019 |

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced ...
Streetwise Reports | April 21, 2020 |

Immunotherapy Firm Releases Data Showing Treatment Potential Against Sepsis

Recently presented results from Enlivex Therapeutics' Phase 1b study in sepsis and their implications are reviewed in an H.C. Wainwright & Co. report. In a June 1 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Enlivex Therapeutics Ltd.'s ...
Streetwise Reports | June 4, 2020 |
1 2 3 4 5 6 7 8 9 10 ...